Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects
- PMID: 6863580
- DOI: 10.1002/j.1552-4604.1983.tb02720.x
Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects
Abstract
Nifedipine kinetics have not been described in clinically relevant detail because of difficulties in formulating a stable preparation for intravenous use and lack of a specific and sensitive assay for plasma nifedipine. We recently developed a gas-chromatographic method and determined conditions in which nifedipine could be protected from photodegradation. Therefore, we evaluated the kinetics and bioavailability of nifedipine in 12 normal subjects after single intravenous (1 mg/5 min) and oral (10 mg) doses. After intravenous dosing, the drug was eliminated with a half-time of 1.77 +/- 0.25 hour, and total clearance was calculated at 0.62 +/- 0.09 liter/kg/hr. With oral drug administration, the elimination half-time was twice as long for the group; but within these subjects, marked variability in the rate of appearance of the drug in plasma was observed, giving profiles consistent with fast and slow absorption. In the latter group, peak plasma drug concentrations were only one third the level seen in those exhibiting a faster absorption profile, although the extent of drug absorption (as derived from areas under the plasma level-time curves) did not vary. Bioavailability was 0.45 +/- 0.08. Untoward effects resulting from the drug's pharmaco-subjects after intravenous administration (flushing).
Similar articles
-
The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers.Br J Clin Pharmacol. 1986 Apr;21(4):385-8. doi: 10.1111/j.1365-2125.1986.tb05211.x. Br J Clin Pharmacol. 1986. PMID: 3707812 Free PMC article.
-
Pharmacokinetics and metabolism of nifedipine.Hypertension. 1983 Jul-Aug;5(4 Pt 2):II18-24. doi: 10.1161/01.hyp.5.4_pt_2.ii18. Hypertension. 1983. PMID: 6862586
-
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.Clin Pharmacol Ther. 1986 Jul;40(1):21-8. doi: 10.1038/clpt.1986.134. Clin Pharmacol Ther. 1986. PMID: 3720176 Clinical Trial.
-
Calcium antagonists. Pharmacokinetic properties.Drugs. 1983 Feb;25(2):113-24. doi: 10.2165/00003495-198325020-00002. Drugs. 1983. PMID: 6339196 Review.
-
Kinetics and dynamics of calcium entry antagonists in systemic hypertension.Am J Cardiol. 1986 Feb 26;57(7):16D-21D. doi: 10.1016/0002-9149(86)90800-3. Am J Cardiol. 1986. PMID: 3513512 Review.
Cited by
-
The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.Br J Clin Pharmacol. 1986 Nov;22(5):565-70. doi: 10.1111/j.1365-2125.1986.tb02936.x. Br J Clin Pharmacol. 1986. PMID: 3790403 Free PMC article. Clinical Trial.
-
The pharmokinetics of isradipine in hypertensive subjects.Eur J Clin Pharmacol. 1990;38(2):209-11. doi: 10.1007/BF00265988. Eur J Clin Pharmacol. 1990. PMID: 2140098 Clinical Trial.
-
Comparative pharmacokinetics of two nifedipine products in capsule form following single oral administration in healthy volunteers.Eur J Drug Metab Pharmacokinet. 1997 Jul-Sep;22(3):259-64. doi: 10.1007/BF03189816. Eur J Drug Metab Pharmacokinet. 1997. PMID: 9358208 Clinical Trial.
-
Isradipine. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of mild to moderate hypertension.Drugs. 1995 Apr;49(4):618-49. doi: 10.2165/00003495-199549040-00009. Drugs. 1995. PMID: 7789292 Review.
-
Nifedipine for postoperative blood pressure control following coronary artery vein grafts.Ann R Coll Surg Engl. 1986 Mar;68(2):73-5. Ann R Coll Surg Engl. 1986. PMID: 3485398 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources